Gene: BTBD10
Official Full Name: BTB domain containing 10provided by HGNC
Gene Summary: Predicted to be involved in phosphatidylinositol 3-kinase/protein kinase B signal transduction; positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; and type B pancreatic cell proliferation. Located in fibrillar center and nucleoplasm. [provided by Alliance of Genome Resources, Apr 2025]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO24986 | BTBD10 Knockout cell line (HeLa) | Human | BTBD10 | 1:3~1:6 | Negative | Online Inquiry |
KO24987 | BTBD10 Knockout cell line (HCT 116) | Human | BTBD10 | 1:2~1:4 | Negative | Online Inquiry |
KO24988 | BTBD10 Knockout cell line (HEK293) | Human | BTBD10 | 1:3~1:6 | Negative | Online Inquiry |
KO24989 | BTBD10 Knockout cell line (A549) | Human | BTBD10 | 1:3~1:4 | Negative | Online Inquiry |
BTBD10 Gene Knockout Cell Lines are specialized cellular models engineered to lack the BTBD10 gene, providing a unique platform for researchers to investigate the gene's role in various biological processes. These knockout cell lines utilize the CRISPR-Cas9 gene-editing technology, a precise and efficient method that enables the selective deletion of the BTBD10 gene. This specific genetic alteration allows for the study of loss-of-function phenotypes, contributing to the understanding of gene function and its implications in cellular pathways.
The key function of BTBD10 Gene Knockout Cell Lines lies in their ability to illuminate the role of the BTBD10 protein in cellular signaling, proliferation, differentiation, and apoptosis. Researchers can utilize these models to elucidate mechanisms underlying diseases such as cancer and neurological disorders, where the BTBD10 gene may serve as a regulatory factor. By examining these knockout lines, scientists can better understand the biological impacts of gene loss, paving the way for potential therapeutic interventions.
From a scientific perspective, these cell lines hold significant relevance in both research and clinical settings. They facilitate high-throughput screening for drug discovery, allowing for the identification of compounds that can compensate for the loss of BTBD10 function. When compared to conventional wild-type cell lines, BTBD10 knockout models demonstrate enhanced specificity in studying gene-related molecular mechanisms, reducing confounding variables that may interfere with experimental results.
Researchers and clinicians can benefit from the unique advantages of these knockout cell lines, which include reproducibility in experiments, a commitment to high-quality, validated genetic engineering, and availability across various cell types. These factors make the BTBD10 Gene Knockout Cell Lines an invaluable resource for advancing genetic research and facilitating breakthroughs in personalized medicine.
At our company, we pride ourselves on our expertise in producing genetically modified cell lines, ensuring that our products meet stringent quality control standards. Our commitment to innovation and scientific integrity empowers researchers and clinicians to push the boundaries of knowledge, driving progress in the life sciences.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.